PT-141 10mg

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist that works by activating key pathways within the central nervous system involved in sexual desire, arousal, and motivation. Unlike traditional erectile dysfunction medications that primarily enhance blood flow, PT-141 acts directly on the brain, offering a unique mechanism of action that is independent of vascular function.

Originally derived from Melanotan II during research into melanin production and skin pigmentation, PT-141 attracted significant scientific interest after researchers observed pronounced effects on sexual arousal and libido. Further investigation identified its activity at melanocortin receptors, particularly MC3R and MC4R, which are involved in regulating sexual behavior, energy balance, and appetite.

By targeting these central nervous system pathways, PT-141 has demonstrated the ability to enhance sexual desire and arousal in both men and women. Its effects extend beyond physical readiness by influencing the neurological processes associated with libido and sexual motivation.

Ships from Canada for fast and reliable domestic fulfillment.

Potential Research Benefits of PT-141

Research and clinical studies have shown that PT-141 may support:

• Enhanced libido and sexual desire in both men and women
• Improved sexual arousal and responsiveness
• Increased genital sensitivity and sexual satisfaction
• Reliable erectile function in men, including some individuals who have not responded adequately to traditional therapies
• Treatment of hypoactive sexual desire disorder (HSDD) in women

PT-141 has been extensively studied in women with hypoactive sexual desire disorder and is the active ingredient in the FDA-approved medication Vyleesi®. In men, research has demonstrated improvements in erectile function and sexual performance through mechanisms distinct from phosphodiesterase-5 (PDE5) inhibitors such as sildenafil and tadalafil.

Because PT-141 does not primarily rely on vascular pathways, it represents a unique area of research for individuals seeking alternatives to conventional erectile dysfunction therapies. Studies suggest onset of effects typically occurs within approximately 45 minutes to 2 hours following administration, with effects mediated through central nervous system activation rather than direct changes in blood flow